2024
A synthetic agent ameliorates polycystic kidney disease by promoting apoptosis of cystic cells through increased oxidative stress
Fedeles B, Bhardwaj R, Ishikawa Y, Khumsubdee S, Krappitz M, Gubina N, Volpe I, Andrade D, Westergerling P, Staudner T, Campolo J, Liu S, Dong K, Cai Y, Rehman M, Gallagher A, Ruchirawat S, Croy R, Essigmann J, Fedeles S, Somlo S. A synthetic agent ameliorates polycystic kidney disease by promoting apoptosis of cystic cells through increased oxidative stress. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2317344121. PMID: 38241440, PMCID: PMC10823221, DOI: 10.1073/pnas.2317344121.Peer-Reviewed Original ResearchConceptsCyst cellsAutosomal dominant polycystic kidney diseaseMouse models of autosomal dominant polycystic kidney diseasePolycystic kidney diseaseModel of autosomal dominant polycystic kidney diseaseKidney diseaseDeveloped primersMitochondrial oxidative stressPathophysiology of autosomal dominant polycystic kidney diseaseOxidative stressInduce apoptosisMitochondrial respirationCystic cellsUp-regulating aerobic glycolysisHomozygous inactivationMonogenic causeDominant polycystic kidney diseaseAerobic glycolysisRenal replacement therapyApoptosisEnd-stage kidney diseaseAnti-tumor agentsAdult mouse modelChronic kidney diseaseAlkylate DNA
2022
Neurospora crassa is a potential source of anti-cancer agents against breast cancer
Han R, Yang H, Ling C, Lu L. Neurospora crassa is a potential source of anti-cancer agents against breast cancer. Breast Cancer 2022, 29: 1032-1041. PMID: 35881300, DOI: 10.1007/s12282-022-01383-9.Peer-Reviewed Original ResearchConceptsBreast cancerT-47DBreast cancer stem cellsBreast cancer cell linesBreast cancer invasivenessCancer stem cell-related genesStem cell-related genesTumor cell proliferationCancer stem cellsMouse model resultsAnti-tumor agentsCell-related genesAnti-cancer agentsCancer cell linesTumor growthCancer invasivenessCancer stemCell proliferationMCF-10ACell linesCancerInhibition rateStem cellsSpheroid formationCASP3 activity
2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.Peer-Reviewed Educational MaterialsConceptsAnaplastic lymphoma kinaseEpidermal growth factor receptorDevelopment of molecular-targeted agentsAdvent of immune checkpoint inhibitorsNon-small-cell lung cancerPredictive biomarkers of responseEmergence of acquired resistanceTreatment approachesAdvanced NSCLC patientsImmune checkpoint inhibitorsProgression-free survivalMolecular targeted agentsBiomarkers of responseNon-small-cellTreatment of patientsCancer-related mortalityGrowth factor receptorMutation-specific inhibitorsAnti-tumor agentsCheckpoint inhibitorsNSCLC patientsGene aberrationsDownstream signaling blockadePredictive biomarkersMolecular subtypes
2010
Aurora kinase inhibitors as anti-cancer therapy
Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anti-Cancer Drugs 2010, 21: 339-350. PMID: 20016367, DOI: 10.1097/cad.0b013e3283350dd1.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAurora Kinase BAurora Kinase CAurora KinasesBenzamidesBenzimidazolesCyclohexanecarboxylic AcidsDrug Screening Assays, AntitumorEnzyme ActivationHumansNeoplasmsOrganophosphatesPhenylurea CompoundsProtein Kinase InhibitorsProtein Serine-Threonine KinasesPyrazolesQuinazolinesThiazolesUreaConceptsNon-small cell lung cancerAurora kinase inhibitorsKinase inhibitorsCell lung cancerUpper gastrointestinal adenocarcinomasCurrent clinical investigationsAnti-cancer therapyAnti-tumor agentsOverview of inhibitorsGastrointestinal adenocarcinomasLung cancerAurora kinasesClinical investigationClinical settingHuman cancersCancer therapyTherapyCancerAurora AInhibitorsKey regulatorHuman aurora kinasesKinaseAurora BAdenocarcinoma
2007
A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)
Beeram M, Krop I, Modi S, Tolcher A, Rabbee N, Girish S, Tibbitts J, Holden S, Lutzker S, Burris H. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). Journal Of Clinical Oncology 2007, 25: 1042-1042. DOI: 10.1200/jco.2007.25.18_suppl.1042.Peer-Reviewed Original ResearchAntibody-drug conjugatesMetastatic breast cancerAdverse eventsT-DM1Breast cancerDose levelsHER2 antibody-drug conjugatesFirst antibody-drug conjugatePhase IOngoing partial responsePrincipal adverse eventsReversible transaminase elevationT-DM1 pharmacokineticsObjective tumor responseHuman phase IDose-dependent decreasePotent anti-tumor agentAntigen-specific monoclonal antibodiesAnti-tumor agentsCancer ptsQ3 weeksResistant HER2Transaminase elevationHepatic transaminasesPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply